Related Experiment Video

Updated: Jul 13, 2026

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes
05:08

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes

Published on: August 24, 2018

Novel inhibitors of glycation and AGE formation

Samuel Rahbar1

  • 1Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA. srahbar@coh.org

Cell Biochemistry and Biophysics
|August 22, 2007
PubMed

Insights

LR-90, a novel compound, effectively treats diabetic kidney disease and hyperlipidemia by inhibiting advanced glycation endproducts (AGEs) and receptor for AGE (RAGE) expression. It shows promise in preventing diabetic atherosclerosis.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Background:

  • Advanced glycation/lipoxidation endproducts (AGEs/ALEs) contribute to diabetic complications.
  • Inhibitors of AGE/ALE formation are crucial for therapeutic development.
  • Previous studies indicated therapeutic effects of novel AGE/ALE inhibitors.

Purpose of the Study:

  • To investigate the effects of compound LR-90 on diabetic nephropathy progression.
  • To assess LR-90's impact on AGE and RAGE protein expression in diabetic kidneys.
  • To elucidate the in vitro mechanism of action of LR-90 in inhibiting AGE formation.

Main Methods:

  • Diabetic rats induced by streptozotocin (STZ) were treated with varying concentrations of LR-90.
  • Evaluated renal function, plasma lipids, kidney histopathology, and AGE/RAGE expression.
  • Conducted in vitro studies to determine LR-90's mechanism against AGE formation and cross-linking.

Main Results:

  • LR-90 protected kidneys by reducing albuminuria and ameliorated hyperlipidemia concentration-dependently.
  • LR-90 significantly decreased kidney AGE/ALE accumulation and RAGE protein expression.
  • In vitro, LR-90 demonstrated antioxidant properties and inhibited AGE-protein cross-linking.

Conclusions:

  • LR-90 is effective in treating diabetic nephropathy and hyperlipidemia by inhibiting AGEs and RAGE.
  • LR-90's antioxidant and anti-glycation properties contribute to its renoprotective effects.
  • LR-90 may be beneficial in delaying diabetic atherosclerosis progression due to RAGE inhibition and anti-lipid peroxidation effects.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.